RLAYRelay Therapeutics, Inc.

Nasdaq relaytx.com


$ 7.59 $ -0.02 (-0.26 %)    

Friday, 13-Sep-2024 15:59:51 EDT
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 7.6
$ 7.59 x 200
$ 7.61 x 100
-- - --
$ 5.70 - $ 12.14
2,550,525
na
1.02B
$ 1.90
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 02-22-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 02-23-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-25-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-27-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-relay-therapeutics-rlay-stock-is-down-17-today

Relay Therapeutics shares are trading lower by 17.8% during Wednesday's session. The company priced its $200 million offering.

 reported-earlier-relay-therapeutics-prices-200m-public-offering-of-28571429-common-shares-at-7share

 The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expec...

 relay-therapeutics-faces-downgrade-over-efficacy-concerns-in-competitive-pi3k-inhibitor-market

Relay Therapeutics shares interim data for RLY-2608 from the ReDiscover study, showing a 57% clinical benefit rate. Oppenheimer...

 b-of-a-securities-maintains-buy-on-relay-therapeutics-raises-price-target-to-24

B of A Securities analyst Jason Gerberry maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target f...

 jp-morgan-maintains-overweight-on-relay-therapeutics-lowers-price-target-to-21

JP Morgan analyst Eric Joseph maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and lowers the price target from ...

 barclays-maintains-overweight-on-relay-therapeutics-raises-price-target-to-17

Barclays analyst Peter Lawson maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from ...

 goldman-sachs-reinstates-buy-on-relay-therapeutics-announces-20-price-target

Goldman Sachs analyst Salveen Richter reinstates Relay Therapeutics (NASDAQ:RLAY) with a Buy and announces $20 price target.

 jefferies-upgrades-relay-therapeutics-to-buy-raises-price-target-to-16

Jefferies analyst Akash Tewari upgrades Relay Therapeutics (NASDAQ:RLAY) from Hold to Buy and raises the price target from $...

 oppenheimer-downgrades-relay-therapeutics-to-perform

Oppenheimer analyst Matthew Biegler downgrades Relay Therapeutics (NASDAQ:RLAY) from Outperform to Perform.

 relay-therapeutics-commences-public-offering-of-200m-of-shares-of-its-common-stock

Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%)...

 relay-therapeutics-advances-towards-pivotal-trial-as-it-shares-encouraging-breast-cancer-data-in-heavily-pretreated-patients

Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION